Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).
Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).
复制标题
DOI：
10.1155/2016/6923730
复制
发表时间：
2016
影响因子：
1.5
通讯作者：
Prabhash K
中科院分区：
文献类型：
--
作者：
Patil VM;Joshi A;Noronha V;Sharma V;Zanwar S;Dhumal S;Kane S;Pai P;D'Cruz A;Chaturvedi P;Bhattacharjee A;Prabhash K
介绍。鼻窦肿瘤对化疗有反应，通常出现在晚期，这使得 NACT 成为改善边缘可切除和局部晚期肿瘤的切除和局部控制的有希望的选择。在此，我们回顾了 25 例接受 NACT 治疗的此类病例的结果。材料和方法。选择接受 NACT 治疗的鼻窦肿瘤患者进行本分析。这些患者接受含铂和依托泊苷的 NACT 治疗 2 个周期。有反应且适合大体全切除的患者接受了手术切除和辅助 CTRT。那些有反应但不适合切除的患者接受了根治性 CTRT。 NACT 治疗后进展的患者接受根治性 CTRT 或姑息性放疗。结果。该队列的中位年龄为 42 岁（IQR 37-47 岁）。 19 名患者 (76%) 出现 NACT 3-4 级毒性。 NACT 的回复率为 80%。 12 名患者 (48%) 接受了 NACT 后手术，9 名患者 (36%) 接受了根治性放化疗。 2 年无进展生存率和总生存率分别为 75% 和 78.5%。结论。 NACT治疗鼻窦肿瘤的缓解率为80%。与我们的历史队列相比，NACT 方案随后进行局部治疗与结果的改善相关。
Introduction. Sinonasal tumors are chemotherapy responsive which frequently present in advanced stages making NACT a promising option for improving resection and local control in borderline resectable and locally advanced tumours. Here we reviewed the results of 25 such cases treated with NACT. Materials and Methods. Sinonasal tumor patients treated with NACT were selected for this analysis. These patients received NACT with platinum and etoposide for 2 cycles. Patients who responded and were amenable for gross total resection underwent surgical resection and adjuvant CTRT. Those who responded but were not amenable for resection received radical CTRT. Patients who progressed on NACT received either radical CTRT or palliative radiotherapy. Results. The median age of the cohort was 42 years (IQR 37–47 years). Grades 3-4 toxicity with NACT were seen in 19 patients (76%). The response rate to NACT was 80%. Post-NACT surgery was done in 12 (48%) patients and radical chemoradiation in 9 (36%) patients. The 2-year progression free survival and overall survival were 75% and 78.5%, respectively. Conclusion. NACT in sinonasal tumours has a response rate of 80%. The protocol of NACT followed by local treatment is associated with improvement in outcomes as compared to our historical cohort.